1800 244 735

Huntington's Disease Therapeutics Conference 2017 – Day 2

Day two of the conference looks at some of the most promising approaches to fighting Huntington’s disease.

Huntingtin lowering therapies

Exciting session planned for this morning, as the conference discusses “Huntingtin lowering” approaches to treating HD.

The first talk is from HDBuzz’s own Ed Wild (University College London), who is interested in developing “biomarkers” for HD trials. A biomarker is a lab test that can be done to track the progression of a disease, or the effect of a treatment. Good disease biomarkers for HD would track the progression of the disease more precisely than simply looking at clinical measurements like movement abnormalities. Tracking the progression of HD is complicated and we don’t have any reliable tests for measuring it in the lab, especially in blood samples. Wild’s group has been developing tests to measure cellular debris released by sick and dying brain cells. As brain cells get sick and die in brain diseases like HD, they release their contents into the cerebrospinal fluid. Some of these debris leak into the blood, where very sensitive new tools allow researchers to measure them. During the course of other brain diseases – like Alzheimer’s and Parkinson’s – brain cell debris levels rise in the blood. Wild’s team has discovered a marker in the blood, released from sick brain cells, that increases consistently as HD progresses. Increasingly severe HD mutations leads to higher levels of brain cell debris in the blood, as does aging. This is exciting – for the first time we can track the health of brain cells from blood samples alone

Next up, Harry Orr (U. Minnesota), who works primarily in a disease called spinocerebellar ataxia 1 (SCA1). Like HD, SCA1 is caused by the expansion of a repetitive stretch of DNA with the sequence “C-A-G”. In SCA1 this genetic stutter occurs in a gene called “Ataxin-1”, not the HD gene. We can learn a lot by comparing how the same type of mutation, when it occurs in different genes, causes brain cells to become sick. Orr’s lab has shown that reducing levels of the mutant gene which causes SCA1 improves symptoms in mice. For many years, Orr’s lab has been using mouse models of SCA1 to try and discover interventions to slow disease. Orr’s lab is using antisense oligonucleotides (ASOs) to reduce levels of Ataxin-1 in the brain, similar to approaches being taken in HD. Comparing results between SCA1 and HD could help understand both diseases better.

Nicole Deglon (Lausanne U.) has worked for many years on huntingtin lowering approaches to HD therapy. She has a special interest in using engineered viruses to deliver huntingtin lowering tools into brain cells. New “gene editing” tools, including one called CRISPR/Cas9, allow researchers to modify DNA in adult cells. Deglon’s team has developed several gene editing tools designed to reduce levels of the HD gene. Using her viruses, Deglon is able to deliver these gene editing tools into the brains of HD mice, where they work very efficiently. One concern about gene editing tools is that the “scissors” that cut the DNA stick around forever, long after they’re needed. Deglon’s team has developed a very cool new trick to turn off the DNA scissors after they inactivate the HD gene. This is an exciting advance – it seems likely to make gene editing in the brain safer in the long-term. Her group has evidence that inactivating gene editing tools leads to less unintended cuts in DNA.

The final speaker in this morning’s huntingtin lowering discussion is Liz Doherty from the CHDI Foundation. The foundation is pursuing a wide range of huntingtin lowering technologies Doherty describes the foundation’s search for a “small molecule” that will lower huntingtin levels. Unlike ASOs or the gene editing tools that Deglon described, a small molecule is a drug that could be taken as a pill. This would be a better way to take medicine, but so far no one has ever identified a small molecule which lowers huntingtin levels. Now CHDI is conducting an exhaustive search of over 130,000 different chemicals, hoping one of them will result in huntingtin lowering. In the first round of searching, they’ve identified 4 different chemicals that result in really robust huntingtin lowering in cells. Important to develop new ways to achieve huntingtin lowering, in case any unexpected concerns arise with other approaches like ASOs. So exciting to see the huge diversity of approaches to achieve huntingtin lowering at different stages of development.

Latest Research Articles

Regulating repetition: Gaining control of CAG repeats could slow progression of Huntington’s disease

Published date: 30 November, 2023

“Somatic expansion” is a hot topic in Huntington’s disease research. Somatic expansion is a process in which CAG repeats lengthen in some cells during aging. It’s thought to control how early HD symptoms appear. A group of researchers from Toronto, Canada recently identified proteins that may play an important role in regulating this process. Understanding ... Read more

Getting to the Root of Huntington's Disease: A Plant-Based Approach

Published date: 15 October, 2023

Researchers studied a fragment of the Huntington’s disease (HD) protein in plants and found a new way to stop it from forming toxic clumps. A special plant protein that the team identified can prevent harmful buildup in plants as well as in some HD model systems, showing potential for this approach as a possible way ... Read more

Could halting CAG expansions be a new treatment for HD?

Published date: 5 October, 2023

A recent paper from a group at UMass Chan Medical School, spearheaded by Dr. Daniel O'Reilly and led by Dr. Anastasia Khvorova, used genetic strategies to lower a protein other than huntingtin. This time the researchers went after a gene called MSH3. This is a gene that’s been getting a lot of attention in Huntington’s ... Read more

Tipping the balance; new insights into HD genetic modifiers

Published date: 1 September, 2023

Genetic modifiers can influence when HD symptoms begin. Some of these genes encode for different types of molecular machines whose normal job is to repair our DNA when it is broken or damaged. A recently published study from scientists at Thomas Jefferson University uncovers details of how these molecular machines help repair damaged DNA structures ... Read more

Drug to treat movement symptoms of HD approved by FDA

Published date: 22 August, 2023

The vast majority of people with Huntington’s disease experience movement symptoms known as chorea. Valbenazine, also known as INGREZZA, has recently been approved by the United States Food and Drug Administration (FDA), allowing doctors in the USA to prescribe this medicine for Huntington’s disease (HD) chorea. In this article we go through the key points ... Read more

Youthful competitors: young brain cells oust the old

Published date: 8 August, 2023

When you lose something, an easy solution can be to just replace it. But what if the something you’ve lost are cells in the brain? Can they simply be replaced? Some researchers have been working toward this for Huntington’s disease (HD) by injecting new cells into the brains of animal models. A recent publication that ... Read more